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Available online 4 October 2016The clinical potential of PARP-1 inhibitors has been recognized N10 years ago, prompting intensive research on
their pharmacological application in several branches of medicine, particularly in oncology. However, natural
or acquired resistance of tumors to known PARP-1 inhibitors poses a serious problem for their clinical implemen-
tation. Present study aims to reignite clinical interest to PARP-1 inhibitors by introducing a newmethod of iden-
tifying highly potent inhibitors and presenting the largest known collection of structurally diverse inhibitors. The
majority of PARP-1 inhibitors known to date have been developed as NAD competitors. NAD is utilized by many
enzymes other than PARP-1, resulting in a trade-off trap between their speciﬁcity and efﬁcacy. To circumvent this
problem, we have developed a new strategy to blindly screen a small molecule library for PARP-1 inhibitors by
targeting a highly speciﬁc rout of its activation. Based on this screen, we present a collection of PARP-1 inhibitors
and provide their structural classiﬁcation. In addition to compounds that show structural similarity to NAD or
knownPARP-1 inhibitors, the screen identiﬁed structurally newnon-NAD-like inhibitors that block PARP-1 activ-
ity in cancer cells with greater efﬁcacy and potency than classical PARP-1 inhibitors currently used in clinic. These
non-NAD-like PARP-1 inhibitors are effective against several types of human cancer xenografts, including kidney,
prostate, and breast tumors in vivo. Our pre-clinical testing of these inhibitors using laboratory animals has
established a strong foundation for advancing the new inhibitors to clinical trials.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Cancer cells1. Introduction
Poly(ADP-ribose) polymerase 1 (PARP-1) is an abundant and ubiq-
uitous nuclear enzyme. When active, it captures NAD+ to assemble
long and branching polymers of Poly(ADP-ribose) (pADPr), modifying
itself, as well as surrounding proteins (D'Amours et al., 1999). Although
DNA repair is commonly accepted as its main function, recent ﬁndings
indicate that PARP-1 also participates in numerous nuclear processes,
including regulation of chromatin and gene expression, ribosome bio-
genesis, nuclear trafﬁc, and epigenetic bookmarking (Krishnakumar et
al., 2008; Thomas & Tulin, 2013). PARP-1 tends to control the expres-
sion of genes involved in cell adhesion and cell-to-cell signaling
(Krishnakumar et al., 2008). Given the multitude of PARP-1 functions,
inhibitors of PARP-1 hold promise for several branches ofmedicine. Pre-
clinical data have shown that PARP-1 inhibitors may mitigate inﬂam-
mation, circulatory shock, stroke, and myocardial infarction (Curtin &
Szabo, 2013). The most extensive research on PARP-1 inhibitors hasFox Chase Cancer Center, 333
. This is an open access article underbeen carried out in oncology (Alberts, 2009; Curtin, 2005). PARP-1 in-
hibitors have been shown to selectively eliminate several types of tu-
morigenic cells, namely BRCA1/2-deﬁcient breast and ovarian cells
(Bryant et al., 2005). Indeed, one PARP-1 inhibitor (Olaparib/Lynparza
™, AstraZeneca) has been approved by both the European Medicines
Agency and FDA to treat advanced ovarian cancer with BRCA1/2 muta-
tions (Brown et al., 2016) Several PARP-1 inhibitors are currently un-
dergoing phase II/III clinical trials in cancers with or without genetic
predisposition, as a monotherapy or in combination with other drugs
(Brown et al., 2016). Therefore, PARP-1 inhibitors have already been
shown to have the potential required to treat a variety of cancer
types, including prostate, colorectal and pancreatic tumors, beyond
BRCA1/2 ovarian cancer (Brown et al., 2016; Deshmukh & Qiu, 2015;
Lupo & Trusolino, 1846). Unfortunately, a number of clinical studies re-
ported setbacks in research on PARP-1-based anticancer therapies
(Guha, 2011). One of the most disappointing studies thus far was the
phase III trial of iniparib with gemcitabine and carboplatin inmetastatic
triple-negative breast cancer (O'Shaughnessy et al., 2014).
Themajority of currently available PARP-1 inhibitors (Supplementa-
ry Table 1) were designed as NAD competitors and generally represent
various memes of nicotinamide pharmacophore (Fig. 1A,B) (Jayle &
Curtin, 2011). Ubiquity of NAD in a cell makes it difﬁcult to completelythe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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these inhibitors to PARP-1 has been tested and conﬁrmed within
the PARP superfamily (Wahlberg et al., 2012). However, little is
known about their effect on other NAD-dependent pathways. Since
classical PARP-1 inhibitors display strong structural similarities to
nucleotides, they tend to obstruct functions of other enzymes that
utilize nucleotides as cofactors, such as kinases (Chuang et al.,
2012; Antolín et al., 2012; Antolin & Mestres, 2014; Passeri et al.,
2015).
To overcome the limitation of NAD-like PARP-1 inhibitors, we set
out to identify molecules that inhibit PARP-1, but maintain structural
independence from NAD (Tulin, 2011). To accomplish this, we
employed a blind screen of a random small- molecule collection con-
taining 50,000 compounds. As noted above, PARP-1 can be regulated
by competing for binding with NAD (D'Amours et al., 1999), as well as
by two additional routes: obstruction of PARP-1 binding with DNA
(Kirsanov et al., 2014) and disruption of PARP-1 interaction with his-
tone H4 (Pinnola et al., 2007). The latter rout of activation is highly spe-
ciﬁc to PARP-1. Instead of targeting NAD-binding to PARP-1, we
searched for molecules that could disrupt PARP-1 activation by the
core histone H4 (Fig. 1C). H4-dependent PARP-1 activation is stronger
and better sustained than DNA-dependent activation (Fig. 1D). Thus,
we designed a new automated approach to screen a large collection of
small molecules, using the H4-dependent route. Besides identifying
NAD competitors, our screen has identiﬁed molecules that show no
similarity to NAD, other nucleotides, or to any known PARP-1 inhibitor.
Further testing of a subset of these compounds demonstrated their efﬁ-
cacy toward PARP-1 inhibition in cancer cells, as well as their ability to
suppress tumorigenesis in prostate and kidney cancer with greater efﬁ-
cacywhen compared to current clinically approved drugs and the NAD-
competitor Olaparib.2. Materials and Methods
2.1. Library Screening
An ELISA-like assay developed in our laboratory and tested on the
ICCB Library of known substances was used to screen a ChemDiv li-
brary of 50,000 small-molecule compounds. The conditions for
screening were based on a published protocol (Antolin & Mestres,
2014). DMSO was used as a negative hit control for this screening,
and 3AB (known PARP-1 inhibitor) was used as a positive hit control
(40 mM concentration as a weak positive control; 400 mM concen-
tration as a strong positive control). Positions of negative controls
on a 384-well plate are were as follows: columns 1 and 2: rows A,
B, G, H, M and N; columns 23 and 24: rows C, D, I, J, O and P. Positions
of weak positive controls on a 384-well plate were as follows: col-
umns 1 and 2: rows C, D, I, J; columns 23 and 24: rows G, H, M, N. Po-
sitions of strong positive controls on a 384-well plate were as
follows: columns 1 and 2: rows E, F, K, L, O, P; columns 23 and 24:
rows A, B, E, F, K, L (Fig. 1F).
Nunc® MaxiSorp™ 384 well plates were coated with histone H4
(3 ng/well) diluted in PBS overnight at RT. Next morning, the plates
were washed with PBS-T and blocked with 5% non-fat milk in PBS-T
for 1 h at RT. NAD+ solution (260 pMol/well) was distributed to each
well, and library compounds and controlswere then added to the plates
(Fig. 1F). PARP1 mix (2×; prepared separately) was then distributed to
NAD+/inhibitors-containing wells, plates were incubated at RT for 1 h
andwashed twice with PBS-T. Plates were then incubatedwith primary
10H antibodies (1:4000 in PBS-T/milk) and secondary HRP-conjugated
goat anti-mouse antibodies (1:1500 in PBST/milk) for 1 h each and
washed twice after every incubation with PBS-T. Plates were developed
with SureBlue reagent, reactions were stopped with Stop solution (1 N
HCl), and absorbance was taken by Perkin Elmer Envision Plate Reader
at 450 nm.2.2. Small-Molecule Clustering Methods
Inhibitor molecules were imported in SMILES format using Canvas,
ver. 1.6 (Canvas, 2013). Binary hashed ﬁngerprints were calculated
from the 2D structure using a dendritic methodology (Duan et al.,
2010). These generated ﬁngerprints were then used as the basis for
clustering inhibitors by twomethods. Theﬁrst utilized hierarchical clus-
teringwith a Tanimoto similaritymetric, and a Schrödinger cluster link-
age method yielded 22 clusters by default. Alteration of the merging
distance parameter in the resulting dendrogram from 0.96 to 0.9
yielded 96 clusters. The second clustering methodology involved self-
organizing maps calculated according to the sum of ﬁngerprint dis-
tances to 27 known PARP inhibitors. Molecules were parsed into a
10 × 10 grid according to this self-organizing approach, measuring sim-
ilarity to known inhibitors. Twenty-seven individual heat maps of the
10 × 10 grid showing distance to individual inhibitors were output for
comparison.
2.3. Fluorescence of NADH assay
Fluorescence of NADH assay was used to monitor the effect of
Olaparib and non-NAD-like inhibitor (5F02) on inhibition of IMPDH ac-
tivity. IMPDH (Inosine-5′-monophosphate dehydrogenase) catalyzes
inosine monophosphate (IMP) with NAD+ as a cofactor to produce
Xanthosinemonophosphate (XMP) andNADH. The reactionmixture in-
cludes 3 μM IMP (Sigma), 5 mM NAD, and 1 μg/μl Recombinant His-
tagged human IMPDH2 enzyme (a gift from Dr. Jeffrey R. Peterson of
Fox Chase Cancer Center) with/without Olaparib (2 mM) or 5F02
(2 mM) in 100 μl of 1× reaction buffer (100 mm Tris-HCl, pH 7.5;
200 mM KCl; 20 mM MgCl2) at 37 °C. NADH concentration was mea-
sured with 340 nm as excitation wavelength and 440 nm as emission
wavelength for 10 min using the Cary Eclipse ﬂuorescence spectropho-
tometer. The reaction ratewas plotted based on an established standard
curve and converted to the speciﬁcity activity of IMPDH (uM NADH/
min/mg). The reaction with or without PARP-1 inhibitors was repeated
ﬁve times. The average value was used for statistical analysis with Stu-
dent t-test.
2.4. Human Cell Cultures
Normal human mammary epithelial cells (HMEC) and Human
breast carcinoma cell line BT474 (Lasfargues et al., 1978) were obtained
from the Matthew Robinson Lab at Fox Chase Cancer Center and cul-
tured in RPMI 1640 with 10% FBS, sodium pyruvate (10 mM), N-2-
hydroxyethylpiperazine-N′-2-ethanesulfonic acid (10 mM) and antibi-
otics. Androgen-independent human PC-3 prostate cancer cells (Teper
et al., 2012) were obtained from ATCC (Rockville, MD). Cells were cul-
tured in RPMI 1640 (Bio-Whittaker, Walkersville, MD) supplemented
with 10% FBS (Hyclone, Logan, UT), penicillin (100 μ/ml), streptomycin
(100 μg/ml), sodium pyruvate (1 mM) and non-essential amino acids
(0.1 mM) under conditions indicated in the ﬁgure legends. The renal
carcinoma cell (PNX) line (RCC) was a kind gift fromDr. Igor Astsaturov
(Fox Chase Cancer Center, Philadelphia, PA). RCC tumor cells were iso-
lated from tumor tissue specimen obtained with written informed con-
sent and Fox Chase Cancer Center Institutional Review Board approval
(IRB approved protocol #12–822) from a patient undergoing tumor re-
section at the Fox Chase Cancer Center.
2.5. PARP-1 Inhibitory Assay in Human Cell Culture
Different doses of new non-NAD-like PARP-1 inhibitors or classical
PARP-1 inhibitors 4ANI and PJ34 were added to the cells cultured in
complete medium. After 24 or 48 h, cells were lysed, and protein sam-
ples were analyzed with SDS-PAGE and Western Blot using anti-
pADPr antibody.
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Normal cells (HMEC) and breast cancer-derived cells (BT474) were
plated at a density of 104 cells/well (100 μl) in a 96-well plate. On thenext day, Olaparib, a NAD-mimetic, or new non-NAD-like inhibitors
(5F02, 4D11, 5A03, 5H03, 1C09) were added (5 μM). Control cells were
grown with DMSO solution added. Cells were grown for 72 h. 20 μl/well
of Alamar Blue Reagent were added; ﬂuorescence readings were taken.
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The assaywas based on a published protocol (Mori et al., 2009). Cells
were plated into 24-well plates at a density of 2000 cells/well. Cells
were allowed to adhere overnight at 37 °C and treated with increasing
concentrations of non-NAD-like PARP-1 inhibitors or classical PARP-1
inhibitor, Olaparib, for 14 days. Colonies were ﬁxed with 70% ethanol
for 10 min and stained with 0.25% methylene blue in 30% ethanol for
10 min. After that, staining solution was removed, and plates were
rinsedwithwater. Colonies consisting of 50 cells ormorewere counted.
Data were ﬁtted to exponential and logarithmic decaymodels using the
nonlinear curve ﬁttingmodule of Statistica 7.0 software. The best ﬁtting
models for each inhibitor are represented on the chart. Plating efﬁcien-
cies (PE) were calculated as follows: PE= number of colonies / number
of cells seeded. The surviving fraction (SF) was calculated as follows:
SF = number of colonies / number of cells seeded × PE.
2.8. Test of PARP-1 Inhibitors with Xenograft Tumor Models
Ectopic PC-3 or RCC xenograft tumors were established in 6-week-
old male C·B17/Icr-scid mice. Animals were treated intraperitoneally
with non-NAD-like inhibitor 5F02 (23 mg/kg), classical PARP-1 inhibi-
tor Olaparib (Olap) (50 mg/kg), docetaxel (i.v. 12.5 mg/kg) for prostate
xenografts, and the multi-targeted tyrosine kinase inhibitor (TKI) suni-
tinib (i.v. 40 mg/kg) for RCC xenograft tumors or vehicle (PBS) 5 days a
week.
2.9. Assessment of In Vivo Triple-Negative Breast Cancer Tumor Growth
Ectopic xenograft tumors were established using MDA-MB-436, a
triple-negative breast cancer cell line. 2× 106 cellswere subcutaneously
injected into the ﬂank region of 6-week-old female NGSmice (NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ, Jackson Laboratory). All animal procedures
were carried out in accordance with the institutional guidelines on ani-
mal care and with appropriate institutional certiﬁcation. Animals were
fed an autoclaved AIN-93 M diet (Harlan Teklad, Madison, WI) and
water ad libitum. Twenty days after the injection of tumor cells, animals
were randomly assigned to the control or experimental groups (n= 5
mice/group). Animals were treated intravenously (I.V.) with non-
NAD-like inhibitor 5F02 (4.5mg/kg), classical PARP-1 inhibitor Olaparib
(Olap) (30 mg/kg) or vehicle (10% 2-hydroxypropyl-β-cyclodextrin,
PBS×1) 3 days a week. Tumors were measured twice weekly, and
their volumes were calculated as Volume = 0.52 × (width)2 × length.
2.10. Western Blotting
For semi-quantitative protein analysis, cells were lysed in 1×SDS
sample buffer [25 mM Tris (pH 6.8), 2% 2-mercaptoethanol, 3% SDS,
0.1% bromophenol blue, and 5% glycerol] at 1 × 107 cells/ml and then
boiled for 5 min. Proteins were resolved by SDS-PAGE and transferred
to i-Blot (Invitrogen). The following antibodies were used: rabbit poly-
clonal anti-PARP-1 (C2–10, Trevigen), anti-alpha-actin (Mouse mono-
clonal, Sigma, #A5441), anti-pADPr (Mouse monoclonal 10H, Tulip,
#1020), and either goat anti-rabbit or anti-mouse secondary antibody
conjugated to horseradish peroxidase (Sigma). Detection wasFig. 1. Designing a new screening strategy to identify PARP-1 inhibitors. A. PARP-1 binds NAD+
Tyr-907, whichmostly interact with the nicotinamide part of NAD. The parts of NAD used to de
from nicotinamide pharmacophore. C. Three ways of PARP-1 regulation: 1) competition with
binding with DNA. Arrowhead shows site of PARP-1 digestion by Caspase 3, which cleaves off
Interaction with the puriﬁed core histone H4 activates PARP1 in a DNA-independent manner
preincubated with randomly broken DNA or core histone H4, followed by mixing with NAD. T
Western blot using anti-pADPr antibody. These data clearly demonstrate that the DNA-bind
activation. E. Schematic representation of the pipeline used to identify PARP-1 inhibitors. F-G
potential inhibitors could be identiﬁed as green or yellow circles corresponding to wells that
signal when compared to positive (yellow) or negative (purple) controls (G).performed with ECL-Plus (Amersham) and HyBlot CL Autoradiography
Film. Image digitizing and quantitative analysis were performed by Od-
yssey v1.2 software (LI-COR, Lincoln, NE).
2.11. PARP-1 Activity Assay
1 μl of H4-histone (1 μg/μl) or endonuclease-digested plasmid DNA
(0.01 μg/μl) was mixed with 25 μl 200 μM NAD and 1 μl of inhibitor/
water. This mixture was combined with 10×PARP-1 reaction buffer
(500 mM Tris, pH 8.0, 250 mM MgCl2, 1% Triton X-100) and 0.7 μl
PARP-1 enzyme (10 unit/μl, Trevigen). All reactions were carried out
for 30 min at room temperature. Samples were examined with SDS-
PAGE and Western Blot using anti-pADPr antibody.
3. Ethics Statement
This study was carried out in strict accordance with the recommen-
dations from the Guide for the Care and Use of Laboratory Animals, as
provided by the American Association of Accreditation of Laboratory
Animal Care (AAALAC).
3.1. Statistics
All data are presented as mean ± SEM. Statistical analyses were
done using 2-tailed Student's t-test. A P value of 0.05 or less was consid-
ered signiﬁcant.
4. Results
4.1. Screening Strategy
To establish a screening platform, we designed a PARP-1 activation
assay in a 384-well ELISA plate coatedwith histoneH4protein-activator
(Kotova et al., 2011a). PARP-1 reactions were performed in each well in
the presence of a single small molecule compound or a positive and a
negative control. Accordingly, we were able to detect compounds that
could disrupt PARP-1 interaction with the H4 activator, compete with
NAD+, or abolish the accumulation of poly (ADP)-ribose, the product
of these reactions (Fig. 1E). pADPr was detected as described in
(Kotova et al., 2011a). Absorbance at 650 or 450 nmwas used as an in-
dicator of PARP-1 activity.
We used the ICCB Known Bioactives Library of 480 compounds,
which includes all popular PARP-1 inhibitors, as the test library for our
screening. In addition to all known PARP-1 inhibitors, the pilot screen-
ing of the test library identiﬁed seven molecules previously unknown
as PARP-1 inhibitors (Supplementary Table 2). Following the pilot
screening, we performed an analysis of 50,000 small compounds,
selecting positive hits which signiﬁcantly reduced PARP-1 activity (Fig.
1F,G). We identiﬁed 903 small molecules inhibiting PARP-1 in a cell-
free system. After eliminating redundancies that displayed negligible
structural differences, we reanalyzed the 639 selected compounds and
conﬁrmed that all strong positive hits were 100% reproducible. A total
of 373 small molecules in this list inhibited PARP-1 at the same, or bet-
ter, level than the commonly used PARP-1 inhibitors 4ANI and PJ34.by NAD-binding pocket organized by three amino acids, including Gly-863, Ser-904 and
velop PARP-1 inhibitors are shown in red. B. Most current PARP-1 inhibitors are developed
NAD for binding, 2) disruption of PARP-1 interaction with histones and 3) obstruction of
DNA binding Zn-ﬁngers of PARP-1, thus abolishing DNA-dependent PARP-1 activation. D.
. Full-length PARP-1 protein (left) and PARP1 protein cleaved by Caspase 3 (right) were
he product of PARP-1 enzymatic activity, poly(ADP-ribose), was detected after PAGE on a
ing domain of PARP1 (Zn-ﬁngers I and II) is not required for histone-dependent PARP1
. Data were visualized in a colour-coded table representing the 384-well plate in which
had minimal pADPr signal (F) or on a graph representing relative numerical value of this
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strated obvious structural similarities to the known PARP-1 inhibitors.
To narrow down the list of small molecules for further analysis, we
used a computational approach. First, we sorted out new PARP-1 inhib-
itors based on the presence of an obvious structural core, similar to
known biologically active molecules. We identiﬁed 10 subgroups
based on this approach (Fig. 2A) (Supplementary Tables 3-1–3-10).
Three hundred and forty-four structurally heterogeneous small mole-
cules without obvious homology to known compounds were assigned
to 11 subgroups (Supplementary Tables 3-11).4.2. N-Methylpiperidin/N-Methylmorpholino/N-Methylpyrrolidine/
dipxolanyl Group
Even without a common structural core molecule, the compounds
could expose their epitopes in a manner similar to that of NAD-like
PARP-1 inhibitors. To eliminate small molecules that displayed 3D
structural similarity to known PARP-1 inhibitors, we used Canvas, ver.
1.6 (Canvas, 2013). This software allowed us to sort out small molecules
by the 3D positions of certain epitopes, or ﬁngerprints. Information
about the structure of small molecules was imported in SMILES format.
We implemented a clustering analysis based on self-organizing maps
calculated as the sum of ﬁngerprint distances for all new PARP-1 inhib-
itors and the 27 known PARP-1 inhibitors and NAD (Supplementary
Table 1). This allowed us to sort our collection of 639 molecules and
their 3D isomers, as well as the 27 known inhibitors, into a 2D matrix,
each cell of which contained similar molecules (Fig. 2B). Thus, greater
similarity was detected in neighboring cells, but such similarity de-
creased with distance. Heat colors were used to represent the degree
of similarity in each cell (Fig. 2C). After superimposing these maps, we
identiﬁed an area of the matrix with no similarity to known PARP-1 in-
hibitors and NAD (Fig. 2C, red square). This area contains 52 small mol-
ecules (Supplementary Table 4), which include a group of 17
structurally related small molecules (Fig. 2D). This subgroup of non-
NAD-like PARP-1 inhibitors was tested further.
These non-NAD-like molecules show a strong capacity to inhibit
PARP-1 in vitro. Structurally, these molecules could be split into two
subgroups (Fig. 2D): the ﬁrst contains the core element 2-(N-
methylpiperidin-1-yl)acetate or 2-(N-methylmorpholino)acetate or 2-
(N-methylpyrrolidine-1-yl)acetate; the second contains the core ele-
ment 1-((1,3-dioxolane-4-yl)methyl)piperidine or 1-((1,3-dioxolane-
4-yl)methyl)N-methylmorpholino or 1-((1,3-dioxolane-4-yl)methyl)
N-methylpyrrolidine. In addition, two molecules show similarities to
the second group in that they also possess dioxolane-4-yl in their struc-
ture (Fig. 2D), but they are otherwise structurally quite distinct. These
17 non-NAD-like PARP-1 inhibitors have no obvious structural homo-
logues among components of eukaryotic enzymatic pathways. There-
fore, they should have greater efﬁcacy and lower toxicity than classical
NAD-like PARP-1 inhibitors.
We conﬁrmed the efﬁcacy of the selected set of new inhibitors using
a cell-free activation assay. Unlike the classical PARP-1 inhibitors PJ34,
Olaparib and 4ANI, these new inhibitors are very effective in suppress-
ing both DNA- and histone-dependent PARP-1 activation pathwaysFig. 2. Identifying non-NAD-like small molecules inhibiting PARP-1 protein. A. Sorting out new
biologically active molecules. Eleven subgroups were identiﬁed. Structural cores and number
PARP-1 inhibitors and NAD based on 3D ﬁngerprints, using the Canvas, ver. 1.6, program. Ba
cells. The number of small molecules with all their 3D isomers in each cell is indicated. C. Com
Similarity is illustrated by heat map. Red corresponds to highest similarity and blue to abs
represents a superimposure of 27 heat maps and reveals the area of matrix (labeled with re
inhibitors. Structural cores: I - 2-(N-methylmorpholino) acetate; II - 2-(N-methylpiperid
yl)methyl)N-methylmorpholino; V - 1-((1,3-dioxolane-4-yl)methyl) piperidine; VI - 1-((1
catalyzing reaction. F. Non-NAD-like inhibitors do not disrupt IMPDH2 activity. Graph sho
Column1: no recombinant human IMPDH2 added in the reaction. Column2: human IMPDH2
reaction. Column 4: human IMPDH2 with 2 mM 5F02 in the reaction. **: P b 0.01.(Supplemental Fig. S1A). Since inhibiting PARP-1 in a cell-free system
does not warrant activity of a compound in the cell, we further tested
selected compounds for their ability to block PARP-1 in human cells.
We used an inosine-5′-monophosphate dehydrogenase (IMPDH)
activity assay (Fig. 2E) to testwhether Olaparib and our lead compound,
5F02, compete with NAD to reduce the production of NADH in the
IMPDH reaction. Olaparib, as a structural analogue of NAD, decreased
IMPDH activity by two-fold, suggesting that Olaparib interferes with
metabolic pathways associated with NAD (Fig. 2F). In contrast, 5F02
showed no signiﬁcant reduction of NADH production in the IMPDH
assay (Fig. 2F). This result conﬁrmed that non-NAD-like inhibitors like
5F02 are more speciﬁc in their mode of action. Speciﬁcity of NAD-like
inhibitors to PARP-1 has been tested and conﬁrmedwithin the PARP su-
perfamily (Wahlberg et al., 2012). Our lead compound 5F02 is also high-
ly speciﬁc for PARP-1 inhibition (Supplemental Fig. S1B).4.3. New PARP-1 Inhibitors Block PARP-1 Activity and Suppress Tumorigen-
ic Potential of Cancer Cells
To determinewhether the new compounds are capable of inhibiting
PARP-1 in a cell-based system, we tested their activity using different
human cancer cells. Previously, we found that breast (BT474), prostate
(PC3), and kidney (PNX0010) cancer cells show an unusually high
level of PARP-1 activity (Kirsanov et al., 2014). Therefore, we used
these cell lines to test the efﬁcacy of PARP-1 inhibition by new and clas-
sical inhibitors.Whenwe cultured these cells with NAD competitors, ei-
ther 4ANI or PJ34, the amount of pADPr was considerably diminished
(Fig. 3A). Likewise, all 17 molecules identiﬁed by our screen showed a
similar magnitude of PARP-1 inhibition in human cancer cells (Fig.
3A). Olaparib and non-NAD-like inhibitors effectively suppressed the
proliferation of breast cancer-derived cells (Supplemental Fig. S2A). Im-
portantly, however, non-NAD-like inhibitors demonstrated no cytotox-
icity to normal cells, while Olaparib suppressed the growth of both
normal and cancer cells (Supplemental Fig. S2A). Moreover, our lead
compound 5F02 shows no cytotoxicity to any of tested normal cell
lines derived from breast, prostate and kidney, while Olaparib signiﬁ-
cantly repressed the viability of these cells (Supplemental Fig. S2B, C, D).
Since the selected panel of new inhibitors demonstrated no cytotox-
icity on normal human cells, we next tested their ability to suppress the
malignant potential of tumor-derived cells. Unlike normal cells, cancer-
derived cells are capable of establishing colonies growing on TC plates
(Maruyama et al., 1975; Cifone & Fidler, 1980; Li et al., 1989). Thus,
we employed a colonogenic assay to examine our lead compound,
5F02. We found that 5F02 consistently suppressed colony growth for
all tested cell types, while Olaparib was signiﬁcantly weaker (Fig. 3B–
G). Interestingly, when equal doses of 5F02 and Olaparib were adminis-
tered,we noticed a synergistic, i.e., additive, effect on increased suppres-
sion of colony growth (Fig. 3B–G).
To further conﬁrm this synergism, we compared the activity of
Olaparib with ﬁve new non-NAD-like inhibitors (5F02, 4D11, 5A03,
5H03, 1C09) separately and in combination, using a PC-3 colonogenic
assay. Although the effects of each individual new compound on the
growth of PC-3 cells varied considerably, all of them suppressed colonyPARP-1 inhibitors based on the presence of an obvious structural core, similar to known
s of molecules falling in each group are indicated. B. Sorting out 639 new plus 27 known
sed on similarity of ﬁngerprints, compounds were sorted to a 2D matrix containing 100
parison of molecules sorted in the matrix with each known PARP-1 inhibitor and NAD.
ence of similarity. Name of inhibitor is indicated above the map. Bottom-right square
d border) containing non-NAD-like compounds. D. Molecular structures of new PARP-1
in-1-yl)acetate; III - 2-(N-methylpyrrolidine-1-yl)acetate; IV - 1-((1,3-dioxolane-4-
,3-dioxolane-4-yl)methyl) N-methylpyrrolidine. E. Schematic illustration of IMPDH2
wing IMPDH speciﬁc- activity in the IMPDH reaction with/without PARP-1 inhibitors.
with 2 ul DMSO in the reaction. Column3: human IMPDH2 with 2 mM Olaparib in the
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Fig. 3. PARP-1 inhibition and tumor cell suppression by classical NAD-mimetic and novel non-NAD-like PARP-1 inhibitors. (A) Non-NAD-like PARP-1 inhibitors block PARP-1 activity in
human cells. A comparative analysis of PARP-1 activity in BT474, PC-3, and RCC cells cultured without and with classical PARP-1 inhibitors, 4ANI or PJ34, and new inhibitors identiﬁed
in our screen. To detect pADPr on Western blot, we used mAb 10H antibody against pADPr. pAb antibody against Actin was used as a loading control. Reduction of pADPr was
detected by Western blotting for inhibitor-treated cells relative to DMSO-treated cells. (B-G) New PARP-1 inhibitors suppress malignancy potential of cancer-derived cells: BT474
(breast cancer) (B); MDA-MB-436 (breast cancer) (C); PC-3 (prostate cancer) (D); DU145 (prostate cancer) (E); 789-P (RCC) (F); PNX0010 (RCC) (G). Calculation of cell survival rate
in (B-G) was based on clonogenic cell survival assays. Cells were plated into 24-well plates. Cells were allowed to adhere overnight and were treated with a non-NAD-like inhibitor
(5F02) (magenta), Olaparib (blue), and both (red) for 14 days. Colonies were counted and plotted on the graph. Data were ﬁtted to exponential and logarithmic decay models using
nonlinear curve ﬁtting module of Statistica 7.0 software. The best ﬁtting models for each inhibitor are represented on the chart. (H-J) Non-NAD-like PARP-1 inhibitors suppress tumor
growth in vivo. 5F02 inhibitor suppresses growth of triple-negative breast cancer MDA-MB-436 (H), androgen-independent PC-3 (I), and renal cell carcinoma (PNX) (J) xenograft
tumors in vivo. Ectopic MDA-MB-436 PC-3 or RCC xenograft tumors were established in 6-week-old male C·B17/Icr-scid mice (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ mice for MDA-MB-436).
Animals were treated intraperitoneally with non-NAD-like inhibitor 5F02 (23 mg/kg), classical PARP-1 inhibitor Olaparib (Olap) (50 mg/kg), docetaxel (i.v. 12.5 mg/kg) for
prostate xenografts, multi-targeted tyrosine kinase inhibitor (TKI) sunitinib (i.v. 40 mg/kg) for RCC xenograft tumors, or vehicle (PBS) 5 days a week. Values shown represent means
(n= 5) + SEM. (J) 5F02 suppresses growth of RCC xenograft tumors. Xenograft tumors were established in 6-week-old male C·B17/Icr-scid mice using PNX0010 RCC cells generated
from a clinical specimen of kidney cancer resistant to sunitinib treatment. Animals were treated with new PARP-1 inhibitor 5F02 (4 mg/kg intravenously (i.v.) or 6 mg/kg orally
(p.o.)), classical PARP-1 inhibitor Olaparib (20 mg/kg, i.v.), sunitinib (40 mg/kg, p.o.), or vehicle 5 days a week. Values shown represent means (n = 5) + SEM. Data were ﬁtted to
exponential growth models using nonlinear curve ﬁtting module of Statistica 7.0 software. (H-J) Data were ﬁtted to exponential growth models using nonlinear curve ﬁtting module
of Statistica 7.0 software. Error bars correspond to standard deviation based on 5 repeats.
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Olaparib alone (Supplemental Fig. S2E). Moreover, non-NAD-like inhib-
itors synergistically enhance the effect of NAD-competitors on the sup-
pression of the growth of colonies (Supplemental Fig. S2F).
In light of encouraging in vitro data, we examined the antitumor activ-
ity of non-NAD-like inhibitor 5F02, using a triple-negative breast cancertumor growth in vivo. Subcutaneous MDA-MB-436 tumors were
established in 6-week-old female NGS mice. Treatment with 5F02 or
Olaparib and assessment of tumor growth were performed as described
in Materials and Methods. As expected, the classical PARP-1 inhibitor
Olaparib slowed down the triple-negative tumor growth. At the same
time, 5F02 suppressed tumor growth with a greater efﬁcacy (Fig. 3H).
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sistant androgen receptor-negative PC-3 prostate cancer and PNX0010
renal cell carcinoma (RCC) xenograft animal models. As demonstrated
in Figs. 3I and J, animals treated with non-NAD-like inhibitor 5F02
showed a signiﬁcantly stronger inhibition of tumor growth relative to
control animals and animals treated with the classical PARP-1 inhibitor
Olaparib. Moreover, non-NAD-like inhibitors demonstrated superior in
vivo antitumor activity compared with clinically relevant anticancer
drugs, i.e., docetaxel (Tannock et al., 2004) for prostate xenografts and
multi-targeted tyrosine kinase inhibitor (TKI) sunitinib (Motzer et al.,
2007) for RCC xenograft tumors. Importantly, treatment with 5F02
was well tolerated by all animals, with no apparent signs of toxicity.
Finally, we tested the oral bioavailability of 5F02. We compared the
ability 5F02 to suppress RCC tumor growth in vivowhen itwasdelivered
intravenously or orally. The graph presented in Fig. 3J demonstrated
that oral delivery of 5F02 (5F02 PO) is as effective as that delivered by
the intravenous route (5F02 IV).
5. Discussion
Clinical interest in PARP-1 has increased over the past decade with
the recognition of its roles in transcription regulation, DNA repair, epi-
genetic bookmarking, and chromatin restructuring. Currently, over
onehundred clinical studies are being carried out to evaluate PARP-1 in-
hibitors, most involving oncology (Feng et al., 2015). Given the initial
promising results for treating certain types of cancer, the impetus is
now focused on ﬁnding more effective and less cytotoxic PARP-1
inhibitors.
Whereas the NAD-dependent route of PARP-1 activation has been
exhaustively exploited for designing new inhibitors, the other two
known routes of activation, namely, the histone H4- and DNA-depen-
dent pathways, remain overlooked. Here we have reported the discov-
ery of new PARP-1 inhibitors using a screen based on PARP-1
enzymatic activation via histone H4 (Passeri et al., 2015; Kotova et al.,
2011b; Thomas et al., 2014). The screening for compounds inhibiting
H4-induced PARP-1 activity also identiﬁed molecules similar in struc-
ture to NAD, including those acting like previously known PARP-1 in-
hibitors. Other inhibitors identiﬁed by the screen represent a new
generation of PARP-1 inhibitors that are not NAD analogues. Because
NAD is a crucial metabolic currency within cells, compounds that
mimic NAD disrupt multiple cellular processes, leading to off-target ef-
fects. Therefore, novel non-NAD-like PARP-1 inhibitors are expected to
possessminimal secondary toxicity, as they target an activationmecha-
nism unique to the PARP-1 enzyme.
Notably, the new non-NAD-like PARP-1 inhibitors demonstrate
higher efﬁcacy against several types of tumors compared to the classical
NAD-like PARP-1 inhibitors. Activation of PARP-1 via histone H4 has
been best described within the context of transcription regulation and
changes in chromatin structure (Kotova et al., 2011b; Thomas et al.,
2014). The expanse of histone-mediated PARP-1 activity, however,
within the various known functions of PARP-1, e.g., DNA repair, is yet
to be fully understood. The mechanism of action of these new- genera-
tion PARP-1 inhibitors is not clear and may involve several routes, e.g.,
obstructing PARP-1 interactionwith H4 or provoking an inhibitory con-
formational change. Inhibiting allosteric regulation of PARP-1 has re-
cently been shown to be another potential approach to the targeting
of PARP-1 function (Steffen et al., 2014).
When PARP-1 inhibitors were ﬁrst evaluated for their potential in
treating cancer, the underlying rationale for their application was to
prevent PARP-1-mediated DNA repair, thereby reducing the survival
potential of carcinogenic cells. Consequently, in oncology, PARP-1 inhib-
itors have been primarily tested either to increase the efﬁcacy of cyto-
toxic therapies or as a monotherapy via synthetic lethality in tumors
with already notable defective DNA repair pathways, namely homolo-
gous recombination. The synthetic lethality approach has beenmost ex-
tensively explored in BRCA1/2-deﬁcient ovarian and breast cancers(Feng et al., 2015). The ﬁrst PARP-1 inhibitor was recently approved
by the FDA to treat ovarian cancer in women with BRCA1/2 mutations
who had already failed three or more chemotherapy treatments. How-
ever, the responses to this therapeutic approach have been dramatically
varied in patients with BRCA mutations, even including improved out-
comes in cohorts of patients with wild-type BRCA genes (Duan et al.,
2010; Ledermann et al., 2012; Ledermann et al., 2014). It has been spec-
ulated that PARP-1 inhibitor efﬁcacy in oncology extends into its role in
regulating transcription and chromatin structure (Maruyama et al.,
1975). Maintaining an active chromatin state for transcribing genes is
the central component in rapidly dividing cells (Lodhi et al., 2014), par-
ticularly those that are carcinogenic (Krishnakumar et al., 2008). It has
also been shown that PARP-1 plays an integral role in transcription reg-
ulation of hormone-dependent cancers (Schiewer & Knudsen, 2014;
Brenner et al., 2011). Overall, it seems clear that the role of PARP-1 in-
hibitors in oncology extends beyond initial experiments that targeted
the role of PARPs in DNA repair.
Apart from oncology, preclinical efﬁcacy of PARP-1 inhibitors inmit-
igating inﬂammation, circulatory shock, myocardial infarction, and
stroke likely results from the inhibition of PARP-1-mediated transcrip-
tion activation (Curtin & Szabo, 2013). It has been shown that transcrip-
tional proﬁles are dramatically altered by PARP-1 inhibition in innate
immune signaling pathways, potentially dampening aberrant inﬂam-
matory activation (Gupte et al., 2015). So far, the introduction of these
inhibitors beyond oncology has been hampered by the possible risks
of toxicity and carcinogenesis, secondary to inhibiting an integral com-
ponent of DNA repair (Maruyama et al., 1975). Therefore, ﬁnding inhib-
itors that are less cytotoxic and more selective toward PARP-1-
mediated transcription would be of considerable clinical interest. How-
ever, the extent of PARP-1-mediated transcription in DNA repair is not
entirely clear. Although it cannot be determined at this time whether
these new inhibitors have a stronger predilection toward targeting
PARP-1-mediated transcription, their antitumor potential and signiﬁ-
cant reduction in cytotoxicity could launch PARP-1 inhibitors further
into other areas of molecular medicine.
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